Ignite Creation Date:
2025-12-24 @ 4:36 PM
Ignite Modification Date:
2026-01-11 @ 5:06 PM
Study NCT ID:
NCT02383966
Status:
COMPLETED
Last Update Posted:
2022-05-13
First Post:
2015-03-04
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer
Sponsor:
Merck KGaA, Darmstadt, Germany
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-07-31
Start Date Type:
ACTUAL
Primary Completion Date:
2018-01-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-12-20
Completion Date Type:
ACTUAL
First Submit Date:
2015-03-04
First Submit QC Date:
None
Study First Post Date:
2015-03-10
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-01-18
Results First Submit QC Date:
None
Results First Post Date:
2019-04-16
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-04-19
Last Update Post Date:
2022-05-13
Last Update Post Date Type:
ACTUAL